10/12/2021 7:13:53 AM
NRx Pharma Says Revised Investigational New Drug Module On Manufacturing Of ZYESAMI Submitted To US FDA
9/29/2021 6:54:04 AM
NRx Pharma Provides Safety Update On ZYESAMI In ACTIV-3b Critical Care Phase 3 Study
9/27/2021 7:21:49 AM
NRx Pharma Announces Improved Survival At One Year In Highly Comorbid COVID-19 Patients Treated With ZYESAMI
8/24/2021 6:53:40 AM
NRx Pharma Completes Private Placement For Purchase Of 2.73 Mln Shares
8/23/2021 9:35:35 AM
NRx Pharma : Participants In High Dose BriLife Investigational Vaccine Trial For COVID-19 Advised Booster Not Necessary
8/19/2021 9:21:20 AM
NRx Pharma Enters Into Agreements With Investors To Purchase 2.73 Mln Shares Of Common Stock In Private Placement
8/16/2021 10:00:48 PM
NRx Pharma Q2 Net Loss Widens To $16.0 Mln From $0.1 Mln Prior Year
8/4/2021 6:54:10 AM
MannKind Partners With NRx Pharm To Explore Dry Powder Formulation Of ZYESAMI Based On Technosphere Platform
7/22/2021 6:53:05 AM
NRx Pharma Unveils First Successful Commercial Formulation For ZYESAMI
7/19/2021 6:52:24 AM
NRx Pharma Presents Evidence ZYESAMI Helps Prevent Cytokine Storm In Patients With COVID-19